Behar Gregory 4
4 · Aimmune Therapeutics, Inc. · Filed Oct 14, 2020
Insider Transaction Report
Form 4
Behar Gregory
Director
Transactions
- Other
Common Stock, $0.0001 par value
2020-10-13−10,192→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2020-10-13$9.60/sh−39,510$379,296→ 0 totalExercise: $24.90→ Common Stock (39,510 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-10-13$1.71/sh−7,500$12,825→ 0 totalExercise: $32.79→ Common Stock (7,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-10-13$16.24/sh−17,500$284,200→ 0 totalExercise: $18.26→ Common Stock (17,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-10-13$14.60/sh−11,432$166,907→ 0 totalExercise: $19.90→ Common Stock (11,432 underlying) - Disposition to Issuer
Common Stock, $0.0001 par value
2020-10-13$34.50/sh−7,840$270,480→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2020-10-13$17.39/sh−15,398$267,771→ 0 totalExercise: $17.11→ Common Stock (15,398 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., and SPN MergerSub, Inc (the "Merger Agreement"), the securities were cancelled and will cease to exist, and no consideration was delivered in exchange for such cancellation.
- [F2]Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) $34.50 per share (the "Offer Price") multiplied by (ii) the number of shares of common stock subject to the RSU.
- [F3]Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.